Krsnaa Diagnostics Posts Strong Q2 Growth with 22% Rise in Profit

Krsnaa Diagnostics reported robust performance in Q2 FY26, recording an all-time high PAT of ₹239 crore, up 22% YoY, on the back of improved margins and operating leverage. Revenue grew 11% to ₹2,060 crore, while EBITDA rose 18% to ₹602 crore, with EBITDA margin expanding 221 bps to 29%. The company served 5.4 million patients and performed 16.4 million tests, even as it significantly enhanced its quality infrastructure—increasing NABL-accredited labs to 57 (up 54%) and NABH-accredited radiology centers to 36 (up 50%). Its retail business surged, with revenue jumping to ₹174 crore from ₹16 crore a year ago, now contributing 8% to total revenue, driven by expansion to 2,878 retail touchpoints (from just 5). With operations across 18 states, over 3,500 collection centers, and networks of 120 labs and 186 CT/MRI centers, Krsnaa is poised to expand further, targeting over 200 imaging centers—potentially making it one of Asia’s largest radiology providers. Committed to affordable healthcare, Krsnaa offers services at ~70% below market rates through public-private partnerships, having served over 75 million patients since inception. The strong financials underscore that scalability and social impact can go hand-in-hand in India’s growing diagnostics sector.